Portfolio of Diabetes Stocks
Here is a sample of 12 stocks that provide diabetes treatments and monitoring.
| 12 Diabetes Stocks | ||
|---|---|---|
Stock Returns & Price Chart | Symbol | Recent Prices & |
| Abbott Laboratories | ABT | |
| AstraZeneca | AZN | |
| DexCom | DXCM | |
| Eli Lilly | LLY | |
| Insulet Corporation | PODD | |
| Lexicon Pharmaceuticals | LXRX | |
| MannKind Corp. | MNKD | |
| Medtronic | MDT | |
| Novo Nordisk | NVO | |
| Provention Bio | PRVB | |
| Senseonics Holdings | SENS | |
| Tandem Diabetes Care | TNDM | |
| Price data from Quandl as of most recent close. | ||
To inspect the performance of the Diabetes Stocks
portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.
The current value of a $10,000 investment is $16,260. The percent return is 62.60%. The annualized return is 10.21%.
| Return Summary for Diabetes Stocks | |
|---|---|
| Start Date | Jun-30-2014 |
| Start Investment | $10,000.00 |
| End Date | Jun-17-2019 |
| Current Value of Investment | $16,260.25 |
| Total Return | 62.60% |
| Annualized Return | 10.21% |
| Min Date | Nov-30-2016 |
| Min Price | $8,940.47 |
| Max Date | Jun-17-2019 |
| Max Price | $16,260.25 |
| # Values | 61 |
| Number Returns | 1,830 |
| Number Profitable Returns | 1,461 |
| Percent Profitable Returns | 79.84% |
| Number Unprofitable Returns | 369 |
| Percent Unprofitable Returns | 20.16% |
| Profitable to Unprofitable Returns Ratio | 3.96 |
NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.